Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 4(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04833205Phase 2Unknown

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Role: lead

NCT04356118Phase 4Unknown

Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Role: lead

NCT04356222Phase 4Unknown

Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Role: lead

NCT02590510Phase 4Unknown

Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis

Role: lead

NCT02686853Phase 4Unknown

Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis

Role: lead

NCT02588196Phase 4Unknown

The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis

Role: lead

All 6 trials loaded